Ney Carter Borges: POAF and Long-Term Outcomes After Cardiac Surgery
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Postoperative Atrial Fibrillation (POAF) After Cardiac Surgery.
In a large prospective, multinational cohort (VISION Cardiac Surgery; n = 12,234), new-onset postoperative atrial fibrillation (POAF) occurred in 31.8 percent of patients within 30 days of surgery, confirming its status as the most frequent postoperative complication.
From a prognostic standpoint, POAF was strongly associated with subsequent atrial fibrillation: 6.9 percent versus 0.6 percent, corresponding to an adjusted hazard ratio (aHR) of 11.30 (95 percent CI 8.17–15.70), indicating a more than 10-fold increased risk.
Regarding hard outcomes between 30 days and 1 year:
- The composite of stroke or vascular death occurred in 2.3 percent versus 1.5 percent (aHR 1.32; 95percent CI 0.99–1.77), not reaching statistical significance after adjustment.
- All-cause mortality was significantly higher in POAF patients (3.0 percent versus 1.7 percent), with an aHR of 1.54 (95 percent CI 1.18–2.00).
Importantly, absolute stroke rates remained low (approximately 0.7 percent overall), suggesting that POAF may function more as a risk marker than a direct causal driver of thromboembolic events.
Therapeutic strategies were heterogeneous: only 39.4 percent of POAF patients received oral anticoagulation at discharge, while 48.8 percent were treated with amiodarone, reflecting substantial global variability in management.
Conclusion: POAF is common and clinically meaningful, conferring increased mortality and markedly higher AF recurrence, but with a modest and statistically uncertain impact on thromboembolic outcomes.
These findings highlight the need for individualized risk stratification and more standardized management strategies.”

Other posts featuring Ney Carter Borges on Hemostasis Today.
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support
-
Nov 17, 2026, 23:34Ahmed Bennis: Is Aspirin Therapy Enough for VTE Prevention After Arthroplasty?